Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Exploring the Characteristics and Profiles of Relapsing Multiple Sclerosis Patients Initiated on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf Region

NCT05266469 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05266469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05266469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Exploring the Characteristics and Profiles of Relapsing Multiple Sclerosis Patients Initiated on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf Region
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
July 26, 2022
Completion date
November 11, 2024
Enrollment
168 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis